The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Characterization of heart rate (HR) changes during crizotinib treatment: A retrospective analysis of 1,053 ALK+ NSCLC patients.
Sai-Hong Ignatius Ou
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Yiyun Tang
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Anna Polli
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Keith D. Wilner
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Patrick Schnell
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer